Nureca Ltd Reports FY26 Growth, Approves Major Capex

Nureca Limited announced its audited financial results for the fiscal year ended March 31, 2026, reporting annual revenue of Rs. 1,472.10 million and a net profit of Rs. 2.97 million for the full year. The company also revealed a significant capital expenditure plan and key management changes.

Reader Takeaway: Annual revenue growth driven by expansion plans, but quarterly losses due to investment fluctuations require monitoring.

What just happened

Nureca Limited has released its audited financial results for the fiscal year 2025-26. The company achieved a consolidated revenue of Rs. 1,472.10 million for FY26, a notable increase from Rs. 1,146.40 million in FY25. However, the fourth quarter (Q4 FY26) saw a net loss of Rs. 66.25 million, contrasting with a profit of Rs. 20.72 million in the same quarter last year. This quarterly loss was primarily influenced by an Rs. 83.37 million fair value loss on investments classified under fair value through profit or loss (FVTPL).

The company's board has approved an incremental capital expenditure of Rs. 100 crore for plant and machinery. This investment is earmarked for manufacturing medical devices, healthcare consumables, and hygiene products at the company's facility in Dera Bassi, Punjab. Additionally, the board approved the purchase of adjacent land for future expansion.

In terms of management, Chief Financial Officer (CFO) Naresh Gupta resigned, citing career opportunities, and has been succeeded by Chander Kant. Several other leadership positions also saw appointments and re-appointments.

Why this matters

The Rs. 100 crore capex signals Nureca's commitment to expanding its manufacturing capabilities, particularly in the growing medical device and healthcare consumables sectors. This investment is crucial for long-term revenue generation and market share expansion. Investors will be keen to see how this capacity expansion translates into operational efficiency and profitability. The company's ability to manage the impact of investment valuation changes on its quarterly earnings will also be a key factor for investors to watch, differentiating core operational performance from financial instrument volatility.

The backstory

Nureca Limited has been focused on expanding its product portfolio and manufacturing base. The company has previously reported a mixed financial performance, with revenue growth often being a key highlight. The Dera Bassi facility has been central to its manufacturing strategy. The recent capex announcement builds on this strategy, aiming to scale up production for high-demand healthcare products.

What changes now

With the Rs. 100 crore capex approval, Nureca is set to enhance its production capacity. This could lead to increased sales volumes and potentially a stronger market position in its product segments over the medium to long term. The appointment of a new CFO, Chander Kant, will be important for overseeing the financial aspects of this expansion and ensuring robust financial reporting. The board's focus on leadership continuity and growth initiatives suggests a strategic push towards operational scaling.

Risks to watch

Execution risks associated with the Rs. 100 crore capex project, including timely completion and cost overruns, are a primary concern. The company's profitability remains sensitive to fluctuations in the fair value of its investments, as demonstrated in Q4 FY26. Any adverse market movements affecting these investments could continue to impact short-term earnings. Furthermore, managing the transition under a new CFO will be critical to maintaining financial discipline and strategic oversight.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

• Revenue FY26: Rs. 1,472.10 million (vs. Rs. 1,146.40 million in FY25)
• Net Profit FY26: Rs. 2.97 million (vs. Rs. -6.68 million in FY25)
• Q4 FY26 Revenue: Rs. 354.05 million (vs. Rs. 317.50 million in Q4 FY25)
• Q4 FY26 Net Profit: Rs. -66.25 million (vs. Rs. 20.72 million in Q4 FY25)
• Approved Capex: Rs. 100 crore

What to track next

Investors should closely monitor the progress of the Dera Bassi expansion project, including plant and machinery procurement and installation timelines. The company's quarterly financial reports will be key to assessing the impact of expanded capacity on revenue and profitability, and understanding how investment valuations are affecting the bottom line. The smooth integration and performance of the new CFO will also be an important factor to observe.